Nucala Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The nucala market research report is one of a series of new reports that provides nucala market statistics, including the nucala industry global market size, regional shares, competitors with the nucala market share, detailed nucala market segments, market trends, and opportunities, and any further data you may need to thrive in the nucala industry. This nucala market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to the rising prevalence of asthma and chronic obstructive pulmonary disease (COPD), growing focus on precision medicine in treating allergic conditions, growing adoption of biologic therapies, increasing healthcare infrastructure, and expanding reimbursement coverage for biologics. Major trends in the forecast period include advancements in targeted therapies, advancements in drug development, technological advancements in biologics, advancements in drug delivery systems, and advancements in combination therapies.

The rising prevalence of asthma is expected to drive the growth of the Nucala market in the coming years. Asthma is a chronic respiratory condition characterized by airway inflammation and narrowing, leading to symptoms such as wheezing, coughing, chest tightness, and shortness of breath, often triggered by allergens or physical activity. Factors such as environmental pollution, allergens, lifestyle changes, urbanization, and genetic predisposition contribute to the increasing prevalence of asthma. Nucala works by targeting and inhibiting interleukin-5 (IL-5), a protein crucial for the growth and activation of eosinophils, which are white blood cells involved in airway inflammation, thereby reducing symptoms and the frequency of asthma exacerbations. For example, the National Asthma Council reported in November 2023 that Australia recorded 467 asthma-related deaths in 2022, up from 355 deaths in 2021. This growing prevalence of asthma is fueling the expansion of the Nucala market.

The increasing incidence of eosinophilic disorders is also expected to contribute to the growth of the Nucala market. Eosinophilic disorders are conditions marked by the excessive production and accumulation of eosinophils, a type of white blood cell, in various tissues, causing inflammation and potential damage. The rising occurrence of these disorders is linked to environmental allergens, changes in dietary habits, genetic predispositions, and improved diagnostic capabilities. Nucala (mepolizumab) targets and inhibits interleukin-5 (IL-5), reducing eosinophil levels and alleviating symptoms associated with these conditions. For instance, the American Gastroenterological Association noted in October 2024 that the prevalence of eosinophilic esophagitis (EoE) had been increasing, affecting 1 in 617 individuals under 65 in 2022, with annual costs projected to reach $1.3 billion in 2024. This trend highlights the growing demand for treatments such as Nucala.

The development of ready-to-use injectable formulations is a key trend in the Nucala market, aiming to enhance patient convenience and treatment adherence. These formulations are pre-prepared and do not require additional dilution or mixing before administration. For instance, in January 2022, GlaxoSmithKline Plc, a UK-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for a 40 mg prefilled syringe of Nucala (mepolizumab). This ready-to-use injectable is designed for children aged 6-11 with severe eosinophilic asthma and allows for convenient at-home administration after caregiver training by a healthcare provider.

The key company operating in the nucala market is GlaxoSmithKline plc.

North America was the largest region in the nucala market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nucala report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nucala market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Nucala (mepolizumab) is a biologic monoclonal antibody that specifically targets interleukin-5 (IL-5), a cytokine that plays a crucial role in the growth, activation, and survival of eosinophils. By inhibiting IL-5, Nucala helps reduce eosinophilic inflammation, thereby alleviating symptoms and decreasing the frequency of exacerbations in patients suffering from severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and other conditions driven by eosinophils.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Nucala is primarily indicated for severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), chronic obstructive pulmonary disease (COPD), and other eosinophilic-related disorders. Severe asthma is a type of asthma that is challenging to manage, requiring higher doses of medication, and is marked by persistent symptoms such as wheezing and breathlessness, even with standard treatments. The medication is available through various distribution channels, including direct sales, retail and online pharmacies, and is used across different settings, such as hospitals, clinics, and home care environments.

The nucala market consists of sales of nucala 100mg injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.